Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are
at risk of severe COVID‐19. Patients and healthy controls (HC; N= 13) received two doses of …

Patients with hematological malignancies have impaired immune response after two doses
of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational …

Patients with B‐cell malignancies have suboptimal immune responses to SARS‐CoV‐2
vaccination and are a high‐risk population for severe COVID19 disease. We evaluated the …

Serologic responses of COVID-19 vaccine are impaired in patients with B-cell lymphoma,
especially those who had recently been treated with anti-CD20 monoclonal antibodies …

Anti‐CD20 antibody treatments prevent humoral responses to vaccines against severe
acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, but the nature of T‐cell …

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies,
suffer high COVID-19-associated morbidity and mortality. The goal of this study was to …

Following a similar report on multiple myeloma, Ghione and colleagues report the expected
observation that patients with non-Hodgkin lymphoma (NHL) receiving anti-B cell therapies …

SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic.
At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but …

Dear Editor, The increasing clinical data with BsAbs has highlighted their toxicity profile
including an alarming rate of COVID-19 and COVID-19 related infection and deaths [1–4] …

Patients with hematologic malignancies have an increased risk of severe COVID‐19
infection. Vaccination against COVID‐19 is especially important in these patients, but …